1
|
Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H, Al Aghbari J, Al Busaidi I, Al Kindi M, Baawain S, Al Alawi A, Al Lawati A, Al Rawahi B, Al-Baimani K, Al Zidi K, Elfatih N, Dawud B, John B, Rehman F, Yousif F, Al Khadouri G, Saber I, Lal J, Gargouri M, Al-Ward M, AbuDraz N, Al Ruqeishi S, Kumar S, Abdelmottaleb W, Al-Naamani Z, Bin Nazar Z, Balkhair O. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis 2020; 103:288-296. [PMID: 33217576 PMCID: PMC7670920 DOI: 10.1016/j.ijid.2020.11.149] [Citation(s) in RCA: 52] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2020] [Revised: 11/09/2020] [Accepted: 11/09/2020] [Indexed: 12/21/2022] Open
Abstract
Objective The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy. Methods A prospective, open-label, interventional study in adults hospitalized with severe COVID-19 pneumonia was conducted. Patients in the interventional arm received subcutaneous anakinra (100 mg twice daily for 3 days, followed by 100 mg daily for 7 days) in addition to standard treatment. Main outcomes were the need for mechanical ventilation and in-hospital death. Secondary outcomes included successful weaning from supplemental oxygen and change in inflammatory biomarkers. Outcomes were compared with those of historical controls who had received standard treatment and supportive care. Results A total of 69 patients were included: 45 treated with anakinra and 24 historical controls. A need for mechanical ventilation occurred in 14 (31%) of the anakinra-treated group and 18 (75%) of the historical cohort (p < 0.001). In-hospital death occurred in 13 (29%) of the anakinra-treated group and 11 (46%) of the historical cohort (p = 0.082). Successful weaning from supplemental oxygen to ambient air was attained in 25 (63%) of the anakinra-treated group compared with 6 (27%) of the historical cohort (p = 0.008). Patients who received anakinra showed a significant reduction in inflammatory biomarkers. Conclusion In patients with severe COVID-19 pneumonia and high oxygen requirement, anakinra could represent an effective treatment option and may confer clinical benefit. Trial registration number ISRCTN74727214.
Collapse
Affiliation(s)
- A Balkhair
- Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - I Al-Zakwani
- Department of Pharmacology & Clinical Pharmacy, College of Medicine & Health Sciences, Sultan Qaboos University, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - M Al Busaidi
- Department of Medicine, Intensive Care, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - A Al-Khirbash
- Department of Pharmacology & Clinical Pharmacy, College of Medicine & Health Sciences, Sultan Qaboos University, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - S Al Mubaihsi
- Department of Medicine, Pulmonology, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - H BaTaher
- Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - J Al Aghbari
- Department of Medicine, Pulmonology, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - I Al Busaidi
- Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - M Al Kindi
- Department of Microbiology and Immunology, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - S Baawain
- Department of Radiology and Molecular Imaging, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - A Al Alawi
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - A Al Lawati
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - B Al Rawahi
- Department of Hematology, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - K Al-Baimani
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - K Al Zidi
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - N Elfatih
- Department of Medicine, Pulmonology, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - B Dawud
- Department of Surgery, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - B John
- Department of Surgery, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - F Rehman
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - F Yousif
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - G Al Khadouri
- Department of Hematology, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - I Saber
- Department of Surgery, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - J Lal
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - M Gargouri
- Department of Surgery, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - M Al-Ward
- Department of Surgery, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - N AbuDraz
- Department of Surgery, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - S Al Ruqeishi
- Department of Hematology, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - S Kumar
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - W Abdelmottaleb
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - Z Al-Naamani
- Department of Medicine, Sultan Qaboos University Hospital, PO Box 35, Alkoudh 123, Muscat, Oman.
| | - Z Bin Nazar
- Faculty of Biological Sciences, University of Leeds, UK.
| | - O Balkhair
- Faculty of Biological Sciences, University of Leeds, UK.
| |
Collapse
|
2
|
Balkhair A, Taher HB, Al Busaidi I, Al Amin M, Al-Khirbash A, Al Adawi B, Al-Siyabi T. Disseminated strongyloidiasis complicated by alveolar hemorrhage, meningitis, and septic shock treated with albendazole and subcutaneous ivermectin. Int J Infect Dis 2019; 86:44-46. [PMID: 31279610 DOI: 10.1016/j.ijid.2019.06.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 06/25/2019] [Accepted: 06/26/2019] [Indexed: 11/30/2022] Open
Abstract
The case of a patient with disseminated strongyloidiasis following chemotherapy for lymphoplasmacytic lymphoma is presented.
Collapse
Affiliation(s)
- A Balkhair
- Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, Oman.
| | - H B Taher
- Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, Oman
| | - I Al Busaidi
- Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, Oman
| | - M Al Amin
- Department of Medicine, Infectious Diseases Unit, Sultan Qaboos University Hospital, Oman
| | - A Al-Khirbash
- Department of Pharmacy, Sultan Qaboos University Hospital, Oman
| | - B Al Adawi
- Department of Microbiology and Immunology, Sultan Qaboos University Hospital, Oman
| | - T Al-Siyabi
- Department of Microbiology and Immunology, Sultan Qaboos University Hospital, Oman
| |
Collapse
|